Thymosin Alpha-1

Description

Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a naturally occurring peptide produced by the thymus gland, known for its ability to modulate the immune system. It has been extensively studied for its involvement in regulating immunity, defending against infections, managing inflammation, and protecting cells. Thymosin Alpha-1 plays a key role in enhancing T-cell activity and supporting innate immune defenses, contributing to its status as one of the most widely researched peptides in immunology.
Due to its potential benefits, it has attracted significant attention in the fields of wellness and regenerative medicine, particularly for applications related to strengthening immune resilience, aiding recovery, promoting healthy aging, and addressing chronic inflammatory disorders.

Primary areas of research interest include:
– Enhancing immune system function
– Supporting the body’s response to viral infections and pathogens
– Balancing inflammatory processes
– Promoting recovery mechanisms and age-related health maintenance

• Status: Approved in over 30 countries (marketed as Zadaxin), but not approved by the FDA. Holds orphan drug designation from the FDA. Anticipated to regain Category 1 compounding status by 2026. Evidence based on human clinical trials.
• Standard dosage: 1.6 mg administered two to three times per week, typically twice weekly, via subcutaneous injection.
• Investigated uses: Immune system support, management of chronic infections, and as an adjunct in cancer therapy.